Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

News Daily News

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

March 06, 2025

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

November 11, 2022

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

October 2022 News Roundup

News Opinion CV Team Dispatch

October 2022 News Roundup

October 01, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Smoking Linked With Worse Outcomes in Hospitalized COVID-19 Patients

News Daily News

Smoking Linked With Worse Outcomes in Hospitalized COVID-19 Patients

Michael O'Riordan

July 29, 2022

Increased Blood Viscosity Tied to Mortality in Hospitalized COVID-19 Patients

News Daily News

Increased Blood Viscosity Tied to Mortality in Hospitalized COVID-19 Patients

July 18, 2022

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

News Daily News

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Michael O'Riordan

May 09, 2022

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

News Daily News

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

March 22, 2022

TCTMD’s Top 10 Most Popular Stories for January 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2022

January 31, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

Score May Help Guide VITT Management After COVID-19 Vaccination

News Daily News

Score May Help Guide VITT Management After COVID-19 Vaccination

September 23, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

News Daily News

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

June 14, 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

News Conference News ACC 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

May 17, 2021

May 2021 News Roundup

News Opinion CV Team Dispatch

May 2021 News Roundup

May 01, 2021

AHA/ASA Offers Advice on Rare Blood Clots Seen After Vaccines for COVID-19

News Daily News

AHA/ASA Offers Advice on Rare Blood Clots Seen After Vaccines for COVID-19

April 30, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.